Belite Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Employees
- 20
- Market Cap
- $1.4B
- Website
- http://www.belitebio.com
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant
Phase 2/3 DRAGON II trial to evaluate Tinlarebant's efficacy, safety, and tolerability in 60 adolescent STGD1 subjects across U.S., U.K., and Japan. Phase 1b completed in Japan. Tinlarebant granted Orphan Drug and Sakigake Designation in Japan. Pivotal global Phase 3 trial (PHOENIX) ongoing with over 200 GA subjects enrolled.
© Copyright 2025. All Rights Reserved by MedPath